Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID)
SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
- EligibilityCriteria: Inclusion Criteria:  Male or Female Subject aged 18-80 years at the time of signing the informed consent  Histologic diagnosis of NHL (based on World Health Organization 2016 criteria) including:  LBCL, including Diffuse Large B Cell Lymphoma (DLBCL) not otherwise specified (NOS) (including DLBCL arising from indolent lymphoma), Primary Mediastinal Large B-Cell Lymphoma (PMBCL), High-Grade B-Cell Lymphoma (HGBCL), and Follicular Lymphoma (FL) Grade 3B FL Marginal Zone Lymphomas (MZL) Mantle Cell Lymphoma (MCL) Relapsed or refractory disease after no more than 1 prior CD19-directed CAR T cell therapy Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 At least 1 measurable (PET-positive) lesion per Lugano classification Life expectancy ≥12 Weeks  Exclusion Criteria:  Prior CD22-directed therapy including CD22-directed CAR T cell therapy or other CD22 -directed antibody or cell therapy (e.g., Natural Killer (NK) cell) History of central nervous system (CNS) involvement of lymphoma within 1 year prior to enrollment. Autologous hematopoietic stem cell transplantation (HSCT) within 3 months before treatment with Lymphodepleting (LD) chemotherapy (or allogeneic HSCT at any time) Active autoimmune disease or any other diseases requiring immunosuppressive therapy or corticosteroid therapy (defined as >10 mg/day prednisone or equivalent) History or presence of CNS disorder, such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement, within 12 months of enrollment. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult